Case Type: Mergers & Acquisitions

Odyssey Marine Exploration, Inc. (NASDAQ: OMEX) related to its merger with American Ocean Minerals Corporation.

McCormick & Company, Incorporated (NYSE: MKC) related to its merger with Unilever’s Foods business. Upon closing of the proposed transaction, McCormick shareholders will own approximately 35.0% of the combined company

Soleno Therapeutics, Inc. (NASDAQ: SLNO) related to its sale to Neurocrine Biosciences, Inc. Under the terms of the proposed transaction, Soleno shareholders are expected to receive $53.00 per share in cash.

Forian Inc. (NASDAQ: FORA) related to its sale to a consortium led by Max Wygod, Chairman and Chief Executive Officer, together with certain other senior executives and existing shareholders of the company. Under the terms of the proposed transaction, Forian shareholders are expected to receive $2.17 per share in cash.

Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) related to its merger with Korsana Biosciences, Inc. Upon the closing of the proposed transaction, Cyclerion shareholders are expected to own approximately 1.5% of the combined company.

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) related to its sale to Biogen, Inc. Under the terms of the proposed transaction, Apellis shareholders are expected to receive $41.00 per share in cash and a non-transferable contingent value right for the right to receive two payments of $2.00 per share each, contingent on certain annual global net sales thresholds being … Read more

Affinity Bancshares, Inc. (NASDAQ: AFBI) related to its sale to Fidelity Bancshares (N.C.), Inc. Under the terms of the proposed transaction, Affinity shareholders are expected to receive $23.00 per share in cash.

Centessa Pharmaceuticals plc (NASDAQ: CNTA) related to its sale to Eli Lilly and Company. Under the terms of the proposed transaction, Centessa shareholders are expected to receive $38.00 per share in cash and one non-transferable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones.

Kezar Life Sciences, Inc. (NASDAQ: KZR) related to its sale to Aurinia Pharmaceuticals Inc. Under the terms of the proposed transaction, Kezar shareholders are expected to receive $6.955 per share in cash and one non-transferable contingent value right.

Olaplex Holdings, Inc. (NASDAQ: OLPX) related to its sale to Henkel US Operations Corporation. Under the terms of the proposed transaction, Olaplex shareholders are expected to receive $2.06 per share in cash.